Know Cancer

or
forgot password

Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)


Phase 2
18 Years
75 Years
Open (Enrolling)
Both
Relapsed NLPHL

Thank you

Trial Information

Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)


Inclusion Criteria:



- relapsed nodular lymphocyte predominant hodgkin lymphoma

- age 18 - 75

- review of diagnosis by experienced pathologist

- no major organ dysfunction

Exclusion Criteria:

- classical hodgkin lymphoma

- CD20 antibody treatment within the last 6 months prior enrollment

- chronic or current infectious disease requirering systemic antibiotics

- other past or current malignancy

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate

Outcome Time Frame:

12 months after end of treatment

Safety Issue:

No

Principal Investigator

Andreas Engert, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Cologne

Authority:

Germany: Paul-Ehrlich-Institut

Study ID:

Uni-Koeln-1432

NCT ID:

NCT01187303

Start Date:

May 2011

Completion Date:

Related Keywords:

  • Relapsed NLPHL
  • Hodgkin Disease
  • Lymphoma

Name

Location